Ionis Neurology: Community Connection

The content on this page is intended for use by US healthcare professionals only.

We are committed to addressing the significant unmet needs across a spectrum of neurologic diseases.1-3

A Leader in the Neurology Community

Ionis provides scholarships for individuals affected by neurologic diseases and funds grants to support physicians and scientists.3-5 See below to learn more about the ways in which Ionis is partnering with and supporting its communities.

Advancing Disease Management Through Collaborations

Ionis Neurology partners with university researchers to identify genetic targets and develop and validate investigational RNA-targeted medicines for neurologic diseases.6-10

Community Leader Table
MECP2, methyl CpG binding protein-2; RTM, RNA-targeted medicine.

Neurology Young Investigator Grant9

The Neurology Young Investigator Grant (YIG) was created by Ionis Neurology to advance high-quality research in the field of Alexander disease (AxD) by early career investigators. This grant will support clinical, basic, translational, and/or outcomes research on the topic of leukodystrophies, with a focus on AxD for up to two years.5

For any questions, please contact Ionis Medical Affairs at [email protected]

The ADAPT x Ionis Hope Scholarship4

In collaboration with Adapt Functional Movement Center, Ionis created a grant program that provides fully sponsored care services, rehabilitation programs, and education to individuals impacted by ALS. As of 2024, this program has issued more than $125,000 in grants.

The Ion-Advanced Research Projects Agency (ARPA) Initiative11

The Ion-ARPA initiative is designed help identify and accelerate disruptive next-wave innovations to advance the development of novel therapeutic technologies.

One of the areas of interest for this grant is developing strategies that enable delivery of large nucleic acid payloads to the central nervous system.


  1. Ionis Pharmaceuticals. Patients & community. Accessed February 5, 2024.
  2. Ionis Pharmaceuticals. 2022 Corporate Responsibility Report. Accessed February 5, 2024.
  3. Ionis Pharmaceuticals. Ionis Innovation Day. October 4, 2023. Accessed February 5, 2024.
  4. Hua Y, Vickers TA, Baker BF, Bennett CF, Krainer AR. Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol. 2007;5(4):e73.
  5. Qiu J, Wu L, Qu R, et al. History of development of the life-saving drug “Nusinersen” in spinal muscular atrophy. Front Cell Neurosci. 2022;16:942976.
  6. Elitt MS, Barbar L, Shick HE, et al. Suppression of proteolipid protein rescues Pelizaeus-Merzbacher disease. Nature. 2020;585(7825):397-403.
  7. Shao Y, Sztainberg Y, Wang Q, et al. Antisense oligonucleotide therapy in a humanized mouse model of MECP2 duplication syndrome. Sci Transl Med. 2021; 13(583):eaaz7785.
  8. Lee D, Chen W, Kaku HN, et al. Antisense oligonucleotide therapy rescues disturbed brain rhythms and sleep in juvenile and adult mouse models of Angelman syndrome. eLife. 2023;12:e81892.
  9. Ionis Pharmaceuticals. Grants & sponsorships. Accessed February 5, 2024.
  10. Ionis Pharmaceuticals. Ion-ARPA. Accessed February 5, 2024.
  11. Cold Spring Harbor Laboratory. Candidate drug for spinal muscular atrophy, with roots in CSHL research, passes major hurdle. August 4, 2016. Accessed February 5, 2024.
  12. Baylor College of Medicine. Study finds antisense oligonucleotides to treat MECP2 disorder. March 15, 2021. Accessed February 5, 2024.
  13. Ionis Pharmaceuticals. HALOS clinical trial update: ION582 in individuals living with Angelman syndrome. 2023. Accessed February 5, 2024.
  14. Case Western Reserve University. Case Western Reserve University grants exclusive license to Ionis Pharmaceuticals to advance antisense therapy for Pelizaeus-Merzbacher disease. January 27, 2022. Accessed February 5, 2024.

Contact Us

For questions or to request information, please contact us.

Innovation thumbnail of dna and test tubes

Ionis is built on a foundation of transformative technologies that target the underlying causes of neurologic diseases.

Learn more about innovation in neurology »

Thumbnail of people laughing

We are committed to addressing the significant unmet needs across a spectrum of neurologic diseases.

Learn more about the Ionis pipeline »

US-GEN-2400029 v1.0 03/2024